(-)-epigallocatechin 3-gallate/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases interleukin-6 concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“After treatment with EGCG, IL-2 and IFN-γ levels were significantly increased (P<0.05 vs. asthma group); IL-4, IL-6 and TNF-α levels were significantly diminished (P<0.05 vs. asthma group).”
Quoted verbatim from Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice.. - Study
- animal · not in humans
- Duration
- 7 days
- Dose
- 10 or 20 mg/kg/day EGCG by caudal vein injection; the sentence does not say which EGCG group
- Population
- Male Balb/c mice with ovalbumin-induced asthma, serum cytokines by cytometric bead array, EGCG-treated groups versus untreated asthma model group
Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice.2018PMID:29916550Permalink
Keep reading
- Everything the graph holds on (-)-epigallocatechin 3-gallate
- Every compound studied against Interleukin-6 concentration
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M454XG33M6ZPS440Y15NXYB5